Drugs / Bendroflumethiazide
Bendroflumethiazide
also known as
Bendrofluazide · Aprinox · Bendroflumethiazide component of corzide · Bendroflumetiazida · Berkozide · Centyl · Naturetin · Naturetin-10 · +7 more
Small molecule targets SLC12A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NATURETIN-5 | — | 1959-12-07 | fda.gov ↗ |
Trials 4
19581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT00380289 | Sep 2006 → ? | essential hypertension | University of Cambridge | Unknown | Met primary |
| — | NCT00429897 | Aug 2006 → Jul 2007 | hypertensive disorder | University of Cambridge | Unknown | No outcome recorded |
| — | NCT00518479 | Sep 2003 → Apr 2004 | hypertensive disorder, hypertensive heart disease | University of Leeds | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT05753059 Comparator | Aug 2023 → Jun 2028 expected | heart failure | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT00648297 Comparator | Aug 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00647660 Comparator | Jul → Aug 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 4 | NCT02235402 Comparator | Dec 1997 → Mar 2000 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bendroflumethiazide | “Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300 ↗ |
| Known as | Aprinox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Bendrofluazide | “either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily” NCT00380289 ↗ |
| Known as | Bendroflumethiazide component of corzide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Bendroflumetiazida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Berkozide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Centyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Naturetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Naturetin-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Naturetin-2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Naturetin-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Neo-bendromax 2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Neo-bendromax 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Neo-naclex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | NSC-758229 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Known as | Urizide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684 ↗ |
| Action | Inhibit | “Thiazide-sensitive sodium-chloride cotransporter inhibitor” CHEMBL1684 ↗ |
| Modality | Small molecule | — CHEMBL1684 ↗ |
| Route | Oral | “single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fasting conditions” NCT00647660 ↗ |
| Target | SLC12A3 | “Thiazide-sensitive sodium-chloride cotransporter inhibitor” CHEMBL1684 ↗ |